Suppr超能文献

被浪费的钱:加拿大的仿制药价格

Money left on the table: generic drug prices in Canada.

作者信息

Law Michael R

机构信息

Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.

出版信息

Healthc Policy. 2013 Feb;8(3):17-25.

Abstract

BACKGROUND

Generic drugs are a major cost-saving opportunity for patients and drug plans. While almost every province has reduced generic drug prices, we have no information on whether these new prices are internationally competitive. Therefore, I compared Canadian prices to those in two other countries.

METHODS

I used 2009 data from the IMS Brogan Canadian CompuScript and PharmaStat databases and studied the 100 most frequently dispensed generic products in Ontario, which has Canada's lowest generic prices. I compared these prices to those in public drug programs in the United States and New Zealand that use tendering. Using these alternative prices, I calculated the potential savings in Ontario.

RESULTS

Of the top 100 generic products, 82 were listed on an international formulary. In 90% of cases, generic products were less expensive in other countries. If Ontario had obtained the lowest comparator price for these products, the annual public sector and overall drug expenditure savings would have been $129 million and $245 million, respectively. Further, the province could have publicly paid for all these generic drugs - both public and private - and saved $87 million compared to current public sector expenditures.

DISCUSSION

Even after recent reforms, generic drug prices in Canada remain high by international standards. I found that if Ontario had obtained commonly used generic drugs at international best prices, the province could have publicly paid for all generic drugs and lowered annual expenditures by nearly a quarter-billion dollars.

摘要

背景

仿制药对于患者和药品计划而言是一个主要的成本节约机会。尽管几乎每个省份都降低了仿制药价格,但我们并不清楚这些新价格在国际上是否具有竞争力。因此,我将加拿大的价格与另外两个国家的价格进行了比较。

方法

我使用了来自IMS Brogan加拿大CompuScript和PharmaStat数据库的2009年数据,研究了安大略省(该省仿制药价格在加拿大最低)最常配发的100种仿制药产品。我将这些价格与美国和新西兰采用招标方式的公共药品计划中的价格进行了比较。利用这些替代价格,我计算了安大略省潜在节省的费用。

结果

在100种最畅销的仿制药产品中,有82种被列入国际药品目录。在90%的情况下,其他国家的仿制药价格更低。如果安大略省为这些产品获得了最低的比较价格,那么公共部门每年节省的支出和总体药品支出分别将达到1.29亿加元和2.45亿加元。此外,该省本可以为所有这些仿制药(包括公共和私人的)支付费用,与目前公共部门的支出相比可节省8700万加元。

讨论

即使经过最近的改革,按照国际标准,加拿大的仿制药价格仍然很高。我发现,如果安大略省以国际最优价格获得常用仿制药,该省本可以为所有仿制药支付费用,并将年度支出降低近2.5亿加元。

相似文献

2
The short-term impact of Ontario's generic pricing reforms.安大略省药品通用定价改革的短期影响。
PLoS One. 2011;6(7):e23030. doi: 10.1371/journal.pone.0023030. Epub 2011 Jul 28.
3
4

引用本文的文献

3
Universal prescription drug coverage in Canada: Long-promised yet undelivered.加拿大全民处方药保险:承诺已久却未实现。
Healthc Manage Forum. 2016 Nov;29(6):247-254. doi: 10.1177/0840470416658907. Epub 2016 Oct 15.
7
Generic drugs in Canada: an examination of tiered pricing.加拿大的仿制药:分层定价研究。
CMAJ. 2015 Oct 6;187(14):1033-1034. doi: 10.1503/cmaj.150395. Epub 2015 Jul 13.

本文引用的文献

1
The road to competitive generic drug prices in Canada.加拿大实现仿制药价格具有竞争力的道路。
CMAJ. 2013 Sep 17;185(13):1141-4. doi: 10.1503/cmaj.121367. Epub 2012 Nov 19.
4
Provincial squeeze on generic prices continues.省级层面针对仿制药价格的挤压仍在持续。
CMAJ. 2011 Oct 4;183(14):E1049-50. doi: 10.1503/cmaj.109-3966. Epub 2011 Sep 6.
10

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验